Stay updated with breaking news from Core Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Toward the end of trading Monday, the Dow traded up 2.25% to 31,626.83 while the NASDAQ rose 2.84% to 13,567.56. The S&P also rose, gaining 2.57% to ...
Shares of electroCore, Inc. (NASDAQ: ECOR) were trading higher Monday following the company’s announcement of an exclusive distribution agreement with ...
Midway through trading Monday, the Dow traded up 2.09% to 31,580.33 while the NASDAQ rose 2.56% to 13,530.07. The S&P also rose, gaining 2.28% to ...
Message : Required fields ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar2 PTY Limited (“Medistar”) whereby Medistar will serve as the exclusive distributor of the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) in Australia, supplying therapy to patients suffering with primary headache disorders. The announcement follows the granting of regulatory approval from the Australian Therapeutic Goods Administration (TGA) ...
2 “gammaCore (nVNS) is the only treatment option, drug or device, that is currently available for the acute and preventive treatment of migraine in adolescents,” said Eric Liebler, Senior Vice President of Neurology at electroCore, Inc. “With their interest in technology and desire to avoid prescription drugs, gammaCore represents a unique treatment for adolescents with migraine. We would like to thank the Division of Neuromodulation and Physical Medicine Devices and their colleagues at the FDA for their efforts to review and clear the expanded label for gammaCore." The label expansio...